NORTH LOUISIANA MEDICAL CENTER
1. Target Overview & Investment Thesis
NORTH LOUISIANA MEDICAL CENTER is a 122-bed safety-net/medicaid heavy in LINCOLN PARISH, LA with $56.1M in net patient revenue and a -19.1% operating margin. The hospital serves a payer mix of 32.1% Medicare, 29.5% Medicaid, and 38.4% commercial.
Thesis: Undervalued. Our ML models identify $4.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -19.1% to -11.8% (+736bps).
| Net Revenue HCRIS | $56.1M |
| Current EBITDA COMPUTED | $-10.7M |
| Operating Margin COMPUTED | -19.1% |
| Occupancy HCRIS | 28.6% |
| Revenue / Bed COMPUTED | $460K |
| Net-to-Gross HCRIS | 17.5% |
| Distress Probability ML | 59.3% |
2. Market Context & Competitive Position
LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of -19.1% places it below the state median. Among 37 size-comparable peers (61-244 beds), the median margin is -3.8%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (61-244), prioritizing same-state peers. 37 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| NORTH LOUISIANA MEDICAL CENTER (Target) | LA | 122 | $56.1M | -19.1% |
| CHILDRENS HOSPITAL | LA | 189 | $523.4M | 6.7% |
| ST. TAMMANY PARISH HOSPITAL | LA | 213 | $434.6M | 4.5% |
| OCHSNER MEDICAL CENTER - BATON | LA | 171 | $371.4M | -11.5% |
| WOMANS HOSPITAL | LA | 228 | $345.8M | -8.8% |
| WEST JEFFERSON MEDICAL CENTER | LA | 199 | $329.9M | -11.9% |
| HIGHLAND MEDICAL CENTER | LA | 198 | $285.1M | -4.1% |
| THIBODAUX REGIONAL HEALTH SYST | LA | 164 | $244.9M | -1.7% |
| SLIDELL MEMORIAL HOSPITAL | LA | 231 | $237.0M | -8.4% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.1M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $1.2M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $1.1M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $1.1M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $683K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $36K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-10.7M |
| + RCM Uplift | +$4.1M |
| Pro Forma EBITDA | $-6.6M |
| Current Margin | -19.1% |
| Pro Forma Margin | -11.8% |
| WC Released (1x) | $2.2M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-16.5M | $-29.5M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-16.5M | $-37.8M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-14.9M | $-29.5M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-14.9M | $-36.6M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-18.2M | $-44.8M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-18.2M | $-55.2M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (29.5%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
| Medium | Low occupancy | At 28.6%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case |
| High | Elevated distress probability | Model estimates 59.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 37 hospitals with 61-244 beds
- Same-state prioritization (n=38)
- Comp margins: P25=-12.1% / P50=-3.8% / P75=4.2%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.